The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 26, 2006
Filed:
Nov. 02, 2001
Nigel H. Greig, Phoenix, MD (US);
Karen T. Y. Shaw, St. Laurent, CA;
Qiang-sheng Yu, Lutherville, MD (US);
Harold W. Holloway, Middle River, MD (US);
Timothy T. Sencrant, Silver Spring, MD (US);
Tada Utsuki, West Chester, PA (US);
Donald Ingram, Ellicott City, MD (US);
Arnold Brossi, Bethesda, MD (US);
Anthony Giordano, Phoenixville, PA (US);
Gordon Powers, Malvern, PA (US);
Diane Davidson, Collegeville, PA (US);
Michael Sturgess, Perkasie, PA (US);
Nigel H. Greig, Phoenix, MD (US);
Karen T. Y. Shaw, St. Laurent, CA;
Qiang-Sheng Yu, Lutherville, MD (US);
Harold W. Holloway, Middle River, MD (US);
Timothy T. Sencrant, Silver Spring, MD (US);
Tada Utsuki, West Chester, PA (US);
Donald Ingram, Ellicott City, MD (US);
Arnold Brossi, Bethesda, MD (US);
Anthony Giordano, Phoenixville, PA (US);
Gordon Powers, Malvern, PA (US);
Diane Davidson, Collegeville, PA (US);
Michael Sturgess, Perkasie, PA (US);
The United States of America as represented by the Department of Health and Human Services, Washington, DC (US);
The National Institutes of Health and Axonyx, Inc., New York, NY (US);
Abstract
The present invention provides compounds and methods of administering compounds to a subject that can reduce βAPP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce βAPP production and that is not tocix in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease βAPP production.